Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pezaro

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?J Mezynski, C Pezaro, D Bianchini, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancerR Leibowitz-Amit, A J Templeton, A Omlin, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abirateroneC Massard, J Mateo, Y Loriot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 10, 2012
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?J Mezynski, C Pezaro, D Bianchini, et al.
British Journal of Cancer|October 31, 2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancerD Bianchini, A Omlin, C Pezaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancerR Leibowitz-Amit, A J Templeton, A Omlin, et al.
Pageof 2